Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,325 questions in 216 reviews · Airways
current versionsNo studies 249 · 10.7%Ungraded 107 · 4.6%Very low 276 · 11.9%Low 751 · 32.3%Moderate 718 · 30.9%High 224 · 9.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mepolizumab intravenous (IV) vs placebo Clinically significant adverse events leading to discontinuation · people with asthma Anti‐IL‐5 therapies for asthma (2022) · Cochrane | Risk ratio 0.72 [0.18, 2.92] | 3 studies · 751 participants | High |
Reslizumab intravenous (IV) vs placebo Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma Anti‐IL‐5 therapies for asthma (2022) · Cochrane | Rate ratio 0.43 [0.33, 0.55] | 2 studies · 953 participants | High |
Reslizumab intravenous (IV) vs placebo Rate of exacerbations requiring emergency department treatment or admission · people with asthma Anti‐IL‐5 therapies for asthma (2022) · Cochrane | Rate ratio 0.67 [0.39, 1.17] | 2 studies · 953 participants | High |
Reslizumab intravenous (IV) vs placebo Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma Anti‐IL‐5 therapies for asthma (2022) · Cochrane | no estimate extracted | 3 studies · 1164 participants | High |
Reslizumab intravenous (IV) vs placebo Health‐related quality of life (ACQ)Scale from: 0 to 6 (lower is better) · people with asthma Anti‐IL‐5 therapies for asthma (2022) · Cochrane | no estimate extracted | 4 studies · 1652 participants | High |
Reslizumab intravenous (IV) vs placebo Pre‐bronchodilator FEV1 (L) · people with asthma Anti‐IL‐5 therapies for asthma (2022) · Cochrane | no estimate extracted | 4 studies · 1652 participants | High |
Mepolizumab subcutaneous (SC) vs placebo Rate of exacerbations requiring emergency department treatment or admission · people with asthma Anti‐IL‐5 therapies for asthma (2022) · Cochrane | Rate ratio 0.36 [0.2, 0.66] | 2 studies · 936 participants | High |
Reslizumab intravenous (IV) vs placebo Serious adverse events · people with asthma Anti‐IL‐5 therapies for asthma (2022) · Cochrane | Risk ratio 0.79 [0.56, 1.12] | 4 studies · 1656 participants | High |
Reslizumab intravenous (IV) vs placebo Clinically significant adverse events leading to discontinuation · people with asthma Anti‐IL‐5 therapies for asthma (2022) · Cochrane | Risk ratio 0.66 [0.43, 1.02] | 4 studies · 1659 participants | High |
Reslizumab subcutaneous (SC) vs placebo Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma Anti‐IL‐5 therapies for asthma (2022) · Cochrane | Rate ratio 0.79 [0.56, 1.11] | 1 study · 464 participants | High |
Reslizumab subcutaneous (SC) vs placebo Rate of exacerbations requiring emergency department treatment or admission · people with asthma Anti‐IL‐5 therapies for asthma (2022) · Cochrane | Rate ratio 0.94 [0.43, 2.05] | 1 study · 464 participants | High |
Reslizumab subcutaneous (SC) vs placebo Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma Anti‐IL‐5 therapies for asthma (2022) · Cochrane | no estimate extracted | 1 study · 464 participants | High |
Reslizumab subcutaneous (SC) vs placebo Health‐related quality of life (ACQ)Scale from: 0 to 6 (lower is better) · people with asthma Anti‐IL‐5 therapies for asthma (2022) · Cochrane | no estimate extracted | 1 study · 464 participants | High |
Reslizumab subcutaneous (SC) vs placebo Health‐related quality of life (SGRQ)Scale from: 0 to 100 (lower is better) · people with asthma Anti‐IL‐5 therapies for asthma (2022) · Cochrane | no estimate extracted | 1 study · 464 participants | High |
Reslizumab subcutaneous (SC) vs placebo Pre‐bronchodilator FEV1 (L) · people with asthma Anti‐IL‐5 therapies for asthma (2022) · Cochrane | no estimate extracted | 1 study · 46 participants | High |
Reslizumab subcutaneous (SC) vs placebo Serious adverse events · people with asthma Anti‐IL‐5 therapies for asthma (2022) · Cochrane | Risk ratio 0.97 [0.53, 1.79] | 1 study · 464 participants | High |
Reslizumab subcutaneous (SC) vs placebo Clinically significant adverse events leading to discontinuation · people with asthma Anti‐IL‐5 therapies for asthma (2022) · Cochrane | Risk ratio 4.87 [0.57, 41.4] | 1 study · 464 participants | Moderate |
Mepolizumab subcutaneous (SC) vs placebo Health‐related quality of life (ACQ)Scale from: 0‐6 (lower is better) · people with asthma Anti‐IL‐5 therapies for asthma (2022) · Cochrane | no estimate extracted | 3 studies · 1231 participants | High |
Benralizumab subcutaneous (SC) vs placebo Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma Anti‐IL‐5 therapies for asthma (2022) · Cochrane | Rate ratio 0.59 [0.52, 0.66] | 4 studies · 3112 participants | High |
Benralizumab subcutaneous (SC) vs placebo Rate of exacerbations requiring emergency department treatment or admission · people with asthma Anti‐IL‐5 therapies for asthma (2022) · Cochrane | Rate ratio 0.68 [0.47, 0.98] | 2 studies · 1537 participants | Moderate |
Benralizumab subcutaneous (SC) vs placebo Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma Anti‐IL‐5 therapies for asthma (2022) · Cochrane | no estimate extracted | 3 studies · 1541 participants | High |
Benralizumab subcutaneous (SC) vs placebo Health‐related quality of life (ACQ)Scale from: 0‐6 (lower is better) · people with asthma Anti‐IL‐5 therapies for asthma (2022) · Cochrane | no estimate extracted | 4 studies · 2791 participants | High |
Benralizumab subcutaneous (SC) vs placebo Pre‐bronchodilator FEV1 (L) · people with asthma Anti‐IL‐5 therapies for asthma (2022) · Cochrane | no estimate extracted | 4 studies · 2786 participants | High |
Benralizumab subcutaneous (SC) vs placebo Serious adverse events · people with asthma Anti‐IL‐5 therapies for asthma (2022) · Cochrane | Risk ratio 0.76 [0.62, 0.93] | 5 studies · 3304 participants | High |
Benralizumab subcutaneous (SC) vs placebo Clinically significant adverse events leading to discontinuation · people with asthma Anti‐IL‐5 therapies for asthma (2022) · Cochrane | Risk ratio 2.04 [1.03, 4.03] | 4 studies · 3253 participants | High |
Mepolizumab subcutaneous (SC) vs placebo Health‐related quality of life (SGRQ)Scale from: 0‐100 (lower is better) · people with asthma Anti‐IL‐5 therapies for asthma (2022) · Cochrane | no estimate extracted | 3 studies · 1231 participants | High |
Mepolizumab subcutaneous (SC) vs placebo Pre‐bronchodilator FEV1 · people with asthma Anti‐IL‐5 therapies for asthma (2022) · Cochrane | no estimate extracted | 3 studies · 1231 participants | High |
Mepolizumab subcutaneous (SC) vs placebo Serious adverse events · people with asthma Anti‐IL‐5 therapies for asthma (2022) · Cochrane | Risk ratio 0.68 [0.46, 1.01] | 3 studies · 1231 participants | High |
Mepolizumab subcutaneous (SC) vs placebo Clinically significant adverse events leading to discontinuation · people with asthma Anti‐IL‐5 therapies for asthma (2022) · Cochrane | Risk ratio 0.6 [0.19, 1.85] | 3 studies · 1231 participants | High |
Mepolizumab intravenous (IV) vs placebo Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma Anti‐IL‐5 therapies for asthma (2022) · Cochrane | Rate ratio 0.53 [0.44, 0.64] | 3 studies · 751 participants | High |
Mepolizumab intravenous (IV) vs placebo Rate of exacerbations requiring emergency department treatment or admission · people with asthma Anti‐IL‐5 therapies for asthma (2022) · Cochrane | Rate ratio 0.52 [0.31, 0.87] | 2 studies · 690 participants | High |
Intervention NR Proportion of people with COPD diagnoses confirmed with spirometry · health professionals managing COPD Educational interventions for health professionals managing chronic obstructive pulmonary disease in primary… (2022) · Cochrane | no estimate extracted | 4 participants | Very low |
Intervention NR Proportion of patients with COPD referred to, participating in or having completed pulmonary rehabilitation · health professionals managing COPD Educational interventions for health professionals managing chronic obstructive pulmonary disease in primary… (2022) · Cochrane | no estimate extracted | 4 studies · 625 participants | Low |
Intervention NR Proportion of patients with COPD prescribed respiratory medication consistent with recommended guidelines · health professionals managing COPD Educational interventions for health professionals managing chronic obstructive pulmonary disease in primary… (2022) · Cochrane | no estimate extracted | 12 studies · 52899 participants | Low |
Intervention NR Proportion of patients with COPD vaccinated against influenza/pneumococcal infections · health professionals managing COPD Educational interventions for health professionals managing chronic obstructive pulmonary disease in primary… (2022) · Cochrane | no estimate extracted | 4 studies · 6846 participants | Moderate |
Intervention NR HRQoL · health professionals managing COPD Educational interventions for health professionals managing chronic obstructive pulmonary disease in primary… (2022) · Cochrane | no estimate extracted | 12 studies · 6526 participants | Low |
Intervention NR Frequency of COPD exacerbations · health professionals managing COPD Educational interventions for health professionals managing chronic obstructive pulmonary disease in primary… (2022) · Cochrane | no estimate extracted | 10 participants | Low |
Intervention NR Patient satisfaction with health care · health professionals managing COPD Educational interventions for health professionals managing chronic obstructive pulmonary disease in primary… (2022) · Cochrane | no estimate extracted | 1 study · 1222 participants | Moderate |
Continuous positive airway pressure (CPAP) plus best supportive care vs best supportive care Central AHI ‐ after 3 months Number of participants: 205(1 RCT) Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | Low |
Adaptive servo ventilation (ASV) vs continuous positive airway pressure (CPAP) Cardiovascular mortality Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs continuous positive airway pressure (CPAP) Serious adverse events Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs continuous positive airway pressure (CPAP) Quality of sleep Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs continuous positive airway pressure (CPAP) Quality of life Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | Very low |
Adaptive servo ventilation (ASV) vs continuous positive airway pressure (CPAP) AHI ‐ after 6 months Number of participants: 17(1 RCT) Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | Low |
Adaptive servo ventilation (ASV) vs continuous positive airway pressure (CPAP) All‐cause mortality Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs continuous positive airway pressure (CPAP) Time to life‐saving cardiovascular intervention Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs bilevel ventilation Central AHI ‐ after 6 weeks Number of participants: 30(1 RCT) Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | Low |
Adaptive servo ventilation (ASV) vs bilevel ventilation Cardiovascular mortality Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs bilevel ventilation Serious adverse events Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Continuous positive airway pressure (CPAP) plus best supportive care vs best supportive care Cardiovascular mortality ‐ after 24 months Number of participants: 258(1 RCT) Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | RR 1.17 [0.68, 2.02] | NR | Low |